Foscarnet is indicated for induction and maintenance therapy of cytomegalovirus (CMV) retinitis in patients with AIDS. Foscarnet is also indicated for the treatment of mucocutaneous Herpes Simplex Virus (HSV) infections, clinically unresponsive to aciclovir in immunocompromised patients. The safety and efficacy of foscarnet sodium hexahydrate for the treatment of other HSV infections (e.g. retinitis, encephalitis); congenital or neonatal disease; or HSV in immunocompetent individuals has not been established. The diagnosis of aciclovir unresponsiveness can be made either clinically by treatment with intravenous aciclovir (5–10 mg/kg t.i.d) for 10 days without response or by in vitro testing. Foscarnet is not recommended for treatment of CMV infections other than retinitis or HSV or for use in non-AIDS or non-immunocompromised patients
Foscavir is indicated for induction and maintenance therapy of cytomegalovirus (CMV) retinitis in patients with AIDS. Foscavir is also indicated for the treatment of mucocutaneous Herpes Simplex Virus (HSV) infections, clinically unresponsive to aciclovir in immunocompromised patients. The safety and efficacy of Foscavir for the treatment of other HSV infections (e.g. retinitis, encephalitis); congenital or neonatal disease; or HSV in immunocompetent individuals has not been established. The diagnosis of aciclovir unresponsiveness can be made either clinically by treatment with intravenous aciclovir (5–10 mg/kg t.i.d) for 10 days without response or by in vitro testing. Foscavir is not recommended for treatment of CMV infections other than retinitis or HSV or for use in non-AIDS or non-immunocompromised patients.